mutated Ligand Binding Site gene DataBase





About Us

Bioinformatics and Systems Medicine Laboratory Bioinformatics and Systems Medicine Laboratory

Gene Summary

Ligand Binding Site Mutation Information

Protein Structure Related Information

Gene Expression and Gene-Gene Network

Phenotype Information

Pharmacological Information

Conservation Information for LBS

Gene summary for LANCL1
Gene summary
Basic gene Info.Gene symbolLANCL1
Gene nameLanC lantibiotic synthetase component C-like 1 (bacterial)
CytomapUCSC genome browser: 2q33-q35
Type of geneprotein-coding
Description40 kDa erythrocyte membrane proteinG protein-coupled receptor 69ALanC (bacterial lantibiotic synthetase component C)-like 1LanC (bacterial lantibiotic synthetase component)lanC-like protein 1
Modification date20141207
dbXrefs MIM : 604155
Ensembl : ENSG00000115365
HPRD : 16040
Vega : OTTHUMG00000132991
ProteinUniProt: O43813
go to UniProt's Cross Reference DB Table
ExpressionCleanEX: HS_LANCL1
BioGPS: 10314
PathwayNCI Pathway Interaction Database: LANCL1
Pathway Commons: LANCL1
ContextiHOP: LANCL1
ligand binding site mutation search in PubMed: LANCL1
UCL Cancer Institute: LANCL1
Assigned class in mutLBSgeneDBC: This gene just belongs to mutLBSgenes.

Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez
GO:0007186G-protein coupled receptor signaling pathway10944443

Ligand binding site mutations for LANCL1

Cancer type specific mutLBS sorted by frequency
LBSAAchange of nsSNVCancer type# samples
cf) Cancer type abbreviation. BLCA: Bladder urothelial carcinoma, BRCA: Breast invasive carcinoma, CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma, COAD: Colon adenocarcinoma, GBM: Glioblastoma multiforme, LGG: Brain lower grade glioma, HNSC: Head and neck squamous cell carcinoma, KICH: Kidney chromophobe, KIRC: Kidney renal clear cell carcinoma, KIRP: Kidney renal papillary cell carcinoma, LAML: Acute myeloid leukemia, LUAD: Lung adenocarcinoma, LUSC: Lung squamous cell carcinoma, OV: Ovarian serous cystadenocarcinoma, PAAD: Pancreatic adenocarcinoma, PRAD: Prostate adenocarcinoma, SKCM: Skin cutaneous melanoma, STAD: Stomach adenocarcinoma, THCA: Thyroid carcinoma, UCEC: Uterine corpus endometrial carcinoma.

Protein structure related information for LANCL1
Relative protein structure stability change (ΔΔE) using Mupro 1.1
Mupro score denotes assessment of the effect of mutations on thermodynamic stability.
  (ΔΔE<0: mutation decreases stability, ΔΔE>0: mutation increases stability)
: nsSNV at non-LBS: nsSNV at LBS

nsSNVs sorted by the relative stability change of protein structure by each mutation
Blue: mutations of positive stability change. and red : the most recurrent mutation for this gene.
LBSAAchange of nsSNVRelative stability change
(MuPro1.1: Jianlin Cheng et al., Prediction of Protein Stability Changes for Single-Site Mutations Using Support Vector Machines, PROTEINS: Structure, Function, and Bioinformatics. 2006, 62:1125-1132)

Structure image for LANCL1 from PDB

Differential gene expression and gene-gene network for LANCL1
Differential gene expression between mutated and non-mutated LBS samples in all 16 major cancer types

Differential co-expressed gene network based on protein-protein interaction data (CePIN)
* Left PPI network was created from samples with mutations in the LBS of LANCL1 and the right PPI network was created from samples without mutations in the LBS of LANCL1. Only genes with p-value < 0.05 are shown.
Red circle: input gene. Orange circle: LBSgene. Blue circle: other gene.


Phenotype information for LANCL1
Gene level disease information (DisGeNet)
Disease IDDisease name# PubMedAssociation type

Mutation level pathogenic information (ClinVar annotation)
Allele IDAA changeClinical significanceOriginPhenotype IDs

Pharmacological information for LANCL1
Gene expression profile of anticancer drug treated cell-lines (CCLE)
Heatmap showing the correlation between gene expression and drug response across all the cell-lines. We chose the top 20 among 138 drugs.We used Pearson's correlation coefficient.
Drug information targeting mutLBSgene (Approved drugs only)
Drug statusDrugBank IDNameTypeDrug structure

Gene-centered ligand-gene interaction network

Ligands binding to mutated ligand binding site of LANCL1 go to BioLip
Ligand IDLigand short nameLigand long namePDB IDPDB namemutLBS

Conservation information for LBS of LANCL1
Multiple alignments for O43813 in multiple species
LBSAA sequence# speciesSpecies
C276LLVHWCHGAPG3Homo sapiens, Mus musculus, Rattus norvegicus
C276LLVHWCHGSPG1Danio rerio
C322KGYGLCHGAAG3Danio rerio, Mus musculus, Rattus norvegicus
C322KGYGLCHGSAG1Homo sapiens
D367GCRTPDTPFSL3Homo sapiens, Danio rerio, Rattus norvegicus
D367GCRTADTPFSL1Mus musculus
E374PFSLFEGMAGT4Homo sapiens, Danio rerio, Mus musculus, Rattus norvegicus
H274RDLLVHWCHGA3Homo sapiens, Mus musculus, Rattus norvegicus
H274RDLLVHWCHGS1Danio rerio
H277LVHWCHGAPGV3Homo sapiens, Mus musculus, Rattus norvegicus
H277LVHWCHGSPGV1Danio rerio
H323GYGLCHGAAGN3Danio rerio, Mus musculus, Rattus norvegicus
H323GYGLCHGSAGN1Homo sapiens
K317YGLLKKGYGLC3Homo sapiens, Mus musculus, Rattus norvegicus
K317RGLLKKGYGLC1Danio rerio
L272DTRDLLVHWCH2Mus musculus, Rattus norvegicus
L272DNRDLLVHWCH1Homo sapiens
L272DARDLLVHWCH1Danio rerio
P366HGCRTPDTPFS3Homo sapiens, Danio rerio, Rattus norvegicus
P366HGCRTADTPFS1Mus musculus
R364GEHGCRTPDTP2Homo sapiens, Rattus norvegicus
R364GRHGCRTPDTP1Danio rerio
R364GEHGCRTADTP1Mus musculus
R44Homo sapiens, Danio rerio, Mus musculus, Rattus norvegicus

Copyright © 2016-Present - The University of Texas Health Science Center at Houston
Site Policies | State of Texas